The Study You Must Do, and the Six Months It Buys.
Regulatory strategy for children — where pediatric studies are legally required, financially rewarded, and almost always planned too late.
Pediatrics Is the Only Field Where the Regulator Both Orders and Pays.
PREA requires pediatric assessments for most new drugs and biologics; BPCA offers six months of additional exclusivity for completing studies the FDA formally requests. One is a mandate, the other an incentive, and they operate on different triggers and different timelines. Sponsors routinely satisfy one and forfeit the other.
The initial Pediatric Study Plan is due no later than 60 days after the End-of-Phase-2 meeting — which means the pediatric strategy has to exist while the adult program is still mid-flight. We build the pediatric plan into the development plan, not after it, because in this field late is expensive in both directions.
PREA compels the study. BPCA pays for it. They trigger differently — and satisfying one does not earn the other.
Four Overlapping Regimes, Two Continents, One Program.
Pediatric obligations arrive from several directions at once. They are not alternatives — a global program answers to all of them, on incompatible schedules.
Pediatric assessment required for most new drugs and biologics. Waivers and deferrals exist, but must be justified — not assumed.
The initial Pediatric Study Plan is due within 60 days of the End-of-Phase-2 meeting. It sets the agreed plan and it arrives early.
Six months of additional exclusivity across the moiety in exchange for completing FDA-requested studies — often worth more than the studies cost.
The EU Paediatric Investigation Plan must be agreed far earlier than the FDA equivalent, and a marketing application is invalid without it.
The PIP is the schedule driver, not the PSP. Europe requires an agreed Paediatric Investigation Plan at a much earlier development stage than the FDA requires a study plan — so global sponsors who pace themselves to the FDA's clock discover the EU obligation is already late. We run both from one pediatric strategy with the EU timeline setting the pace.
Children Are Not Small Adults — and the Regulation Says So.
Every technical problem in pediatric development comes from the same fact: the population changes as it grows, and cannot consent.
Extrapolation
Where a similar disease course and exposure-response let you borrow adult efficacy and study only PK and safety — the single biggest lever in pediatric development.
Dose Selection
Model-informed dosing across age bands and weights, where allometric scaling and organ maturation break the adult assumptions.
Age-Appropriate Formulation
A tablet a four-year-old cannot swallow is a program that cannot run — and the formulation work has its own CMC and bridging burden.
Ethics & Consent
Parental permission, child assent, and the risk categories in the regulations that limit what may be done to a healthy child.
Waivers & Deferrals
Where the disease does not occur in children or studies are impossible — a justification the agency must accept, not a box you tick.
Pediatric Device Pathways
Small populations, growing anatomy, and the HDE route that exists because pediatric device markets rarely support a PMA.
Extrapolation turns a pediatric efficacy trial into a PK and safety study — if the argument is built, not assumed.
Extrapolation Is the Difference Between a Study and a Program.
If the disease course and the exposure-response relationship are sufficiently similar between adults and children, the agency's framework allows efficacy to be extrapolated — leaving a pharmacokinetic and safety study rather than a full pediatric efficacy trial. That single determination can remove years and tens of millions from a pediatric obligation.
But it is a scientific argument, not a request. It needs disease-similarity evidence, an exposure-response case, and a modelling package assembled deliberately. We build the extrapolation argument as its own deliverable and take it to the agency early, because the alternative is a trial in children that did not have to happen.
The Pediatric Clock Starts Before You Think It Does.
Almost every pediatric problem we are called into is a timing problem that became a scientific one.
after the End-of-Phase-2 meeting is the deadline for the initial Pediatric Study Plan — while the adult program is still running.
of additional exclusivity is what BPCA offers for completing requested studies. For a large product that is frequently the highest-return work in the portfolio.
The Paediatric Investigation Plan must be agreed earlier than the FDA's plan. Pace to the FDA and the EU obligation is already behind.
Six Failure Modes We Are Brought In to Prevent.
Pediatric obligations are the most predictable deadlines in drug development, and the most frequently missed.
The PSP as an afterthought
Assembling the study plan against a 60-day deadline nobody diaried, and filing a placeholder the division rejects.
Extrapolation assumed, not argued
Planning a PK-only study without the disease-similarity and exposure-response package that justifies borrowing adult efficacy.
PIP timing missed
Pacing the global pediatric strategy to the FDA's clock and arriving at the EU application without an agreed PIP.
No age-appropriate formulation
Reaching the pediatric study with an adult tablet, and pausing the program to develop and bridge a formulation children can take.
BPCA forfeited
Completing PREA-required studies without the Written Request mechanics, and doing the work while leaving the exclusivity on the table.
Consent architecture wrong
An assent and permission plan that does not fit the risk category, and an IRB that will not approve the protocol as written.
Pediatric Regulatory Leadership That Starts on Time.
Our pediatric leads have negotiated PSPs and PIPs, built extrapolation arguments the agency accepted, and captured BPCA exclusivity on major products.
"Pediatric development is the most schedulable work in the industry and the most commonly late. The plan is due sixty days after End-of-Phase-2 — everything good follows from taking that literally."
The discipline we bring across extrapolation, dosing, formulation, and global pediatric obligations.
Facing a Pediatric Obligation? The Deadline Is Earlier Than Your Plan.
Bring senior pediatric regulatory leadership in before End-of-Phase-2, while extrapolation and the study plan are still shapeable.
Senior-led. Embedded in your team. No junior hand-offs.